FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic...

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer.
• BRCA mutations (BRCAm) are a subset of homologous recombination repair mutations (HRRm) found in mCRPC patients.
• Standard treatment for mCRPC often involves androgen deprivation therapy, but resistance develops.

Purpose of the Study:

• To evaluate the efficacy and safety of a fixed-dose combination (FDC) of niraparib and abiraterone acetate (AA) with prednisone (P).
• To support the FDA approval for adult patients with BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

Main Methods:

• A double-blind, randomized trial (MAGNITUDE study, NCT03748641) assigned 423 patients with mCRPC and HRRm.
• Patients received either niraparib plus AA and P, or placebo plus AA and P.
• BRCAm status was a stratification factor, and radiographic progression-free survival (rPFS) was the primary endpoint.

Main Results:

• The niraparib + AA + P arm showed a median rPFS of 16.6 months versus 10.9 months in the placebo arm for the BRCAm subpopulation (HR 0.53; p=0.0014).
• While rPFS improved in the all-HRRm population, FDA analyses indicated the benefit was primarily driven by the BRCAm subgroup.
• Increased toxicity was observed, including anemia requiring transfusion in 27% of patients in the combination arm.

Conclusions:

• The FDA approved the niraparib + AA + P FDC for adult patients with BRCAm mCRPC.
• The approval was based on the significant improvement in rPFS demonstrated in the BRCAm subpopulation of the MAGNITUDE trial.
• The study highlights the importance of genetic biomarkers in guiding prostate cancer treatment decisions.